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Abstract: Introduction: Thoracic re-irradiation remains a challenge regarding the balance of local efficacy
and acceptable toxicities. In this retrospective analysis we analyzed dosimetrical and clinical data of pa-
tients treated with thoracic re-irradiation based on accumulated EQD2Gy doses. Methods and material:
We retrospectively analyzed the data of 42 consecutive single-institutional patients treated with repeated
courses of thoracic radiotherapy from 12/2011 to 01/2017. Accumulated EQD2 dose distributions were
calculated and dose parameters for organs at risk and target volumes were analysed. Results: The median
prescription dose was 42.2 Gy (10–70.6 Gy) for all RT courses. The median Dmean of both lungs was
10.1 Gy3 (range: 1.9 Gy3–17.9 Gy3) with a maximum D0.1 cc of 253.86 Gy3. The median D0.1 cc of
the esophagus was 62.2 Gy3 with a maximum of 103.78 Gy3. The maximum D0.1 cc for the bronchial
tree was 187.33 Gy3 (median 74.35 Gy3) and for the Aorta 216.1 Gy3 (median 70.9 Gy3). Median OS
after first re-irradiation was 19 months (range 1–45 months). 12-month local control after a course of
re-irradiation was 52.6%. 80% of patients suffered from a G1–G2 toxicity, most frequently coughing. One
patient suffered from a G5 complication probably unrelated to re-irradiation. Conclusion: Even though
several organs at risk received maximum accumulated doses of >100 Gy3, thoracic reirradiation resulted
in an acceptable toxicity profile. Local tumor control and overall survival remained encouraging even
after multiple courses of thoracic radiotherapy.
DOI: https://doi.org/10.1016/j.radonc.2020.07.033






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Schröder, C; Stiefel, I; Tanadini-Lang, Stephanie; Pytko, I; Vu, E; Guckenberger, Matthias; Andratschke,
Nicolaus (2020). Re-irradiation in the thorax – An analysis of efficacy and safety based on accumulated
EQD2 doses. Radiotherapy and Oncology, 152:56-62.
DOI: https://doi.org/10.1016/j.radonc.2020.07.033
Original Article
Re-irradiation in the thorax – An analysis of efficacy and safety based on
accumulated EQD2 doses
C. Schröder a,b, I. Stiefel a, S. Tanadini-Lang a, I. Pytko a, E. Vu a, M. Guckenberger a, N. Andratschke a,⇑
aDepartment of Radiation Oncology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; bCanter for Proton Therapy, Paul Scherrer-Institut, Villigen, Switzerland
a r t i c l e i n f o
Article history:
Received 26 March 2020
Received in revised form 13 July 2020
Accepted 20 July 2020







a b s t r a c t
Introduction: Thoracic re-irradiation remains a challenge regarding the balance of local efficacy and
acceptable toxicities. In this retrospective analysis we analyzed dosimetrical and clinical data of patients
treated with thoracic re-irradiation based on accumulated EQD2Gy doses.
Methods and material: We retrospectively analyzed the data of 42 consecutive single-institutional
patients treated with repeated courses of thoracic radiotherapy from 12/2011 to 01/2017.
Accumulated EQD2 dose distributions were calculated and dose parameters for organs at risk and target
volumes were analysed.
Results: The median prescription dose was 42.2 Gy (10–70.6 Gy) for all RT courses. The median Dmean of
both lungs was 10.1 Gy3 (range: 1.9 Gy3–17.9 Gy3) with a maximum D0.1 cc of 253.86 Gy3. The median
D0.1 cc of the esophagus was 62.2 Gy3 with a maximum of 103.78 Gy3. The maximum D0.1 cc for the
bronchial tree was 187.33 Gy3 (median 74.35 Gy3) and for the Aorta 216.1 Gy3 (median 70.9 Gy3).
Median OS after first re-irradiation was 19 months (range 1–45 months). 12-month local control after
a course of re-irradiation was 52.6%. 80% of patients suffered from a G1–G2 toxicity, most frequently
coughing. One patient suffered from a G5 complication probably unrelated to re-irradiation.
Conclusion: Even though several organs at risk received maximum accumulated doses of >100 Gy3, tho-
racic reirradiation resulted in an acceptable toxicity profile. Local tumor control and overall survival
remained encouraging even after multiple courses of thoracic radiotherapy.
 2020 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology 152 (2020) 56–62 This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Thoracic re-irradiation for primary or metastatic intrathoracic
lesions remains a challenge regarding the balance of a locally effec-
tive treatment and acceptable treatment related toxicities. Patients
with primary lung tumors have a high risk of locoregional recur-
rence, a second primary lung cancer or thoracic metastases [1–3].
Besides patients with primary lung cancer, also patients with other
primary tumors might require repeated treatment for intrathoracic
metastases [4–7].
In the past, re-irradiation was often limited to a palliative treat-
ment dose. With the introduction of intensity-modulated and
image-guided radiotherapy as well as stereotactic body radiother-
apy (SBRT), conformal and more precise treatment has become
possible with the ability to deliver locally ablative radiation doses
with acceptable treatment related toxicities [6,8–10]. This also
applies to re-irradiation, e.g. in patients with locoregionally recur-
rent primary tumor or patients in an oligometastatic setting for
whom a curative treatment intend may still apply. Another group
of patients may benefit from palliative re-irradiation to ease tumor
related symptoms like pain or dyspnea [11–16].
Several mostly retrospective analyses of thoracic re-irradiation
that published in the recent years. Most studies described the re-
irradiation plans only separately and independently from each
other; few studies calculated accumulated dose distributions of
the physical dose distributions to better describe the radiation
doses administered both to the target volume and the organs at
risk. Especially regarding SBRT the results are promising with a
good efficacy and acceptable toxicity [6–10,17,18].
Although these data are encouraging the true tolerance of
organs at risk is largely unknown and the decision of re-
irradiation is mostly based on personal experience. The goal of this
analysis was to estimate the tolerance of thoracic organs-at-risk
(OAR) to re-irradiation by calculating accumulated dose distribu-
tions using deformable image registration and dose conversion to
2 Gy biologically equivalent doses (EQD2).
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Methods and materials
Patient characteristics
We retrospectively analyzed the data of 42 patients that
received repeated high-dose thoracic radiotherapy from December
2011 to January 2017. Repeated high-dose radiotherapy was
defined as: (a) at least two courses of thoracic radiotherapy, (b)
at least one course consisting of a radical radiotherapy regimen
of at least 50 Gy in 2 Gy equivalent, (c) overlap of at least the
50% isodose levels from 2 courses. The local ethics committee
approved this retrospective analysis (BASEC-Nr: 2017-01027).
Most patients had non-small cell lung cancer (NSCLC, n = 20), fol-
lowed by esophageal cancer (n = 6) and small-cell lung cancer
(SCLC, n = 4). All patients were discussed in a multidisciplinary
tumor board prior to treatment. Independent of the thoracic radio-
therapy, patients also received additional radiotherapy to other
anatomical sites, e.g. analgetic radiotherapy for painful bone
metastases. During the initial treatment course before re-
irradiation, 69% of patients received systemic therapy, most of
which received chemotherapy (85.7% of patients receiving sys-
temic therapy) followed by the combined treatment with
chemotherapy and immunotherapy (7.1%). Following first re-
irradiation, 52.4% of patients received systemic therapy, again
mostly chemotherapy (68.2% of patients receiving systemic ther-
apy) followed by immunotherapy (22.7%). Further patient charac-
teristics are shown in Table 1.
Radiation treatment planning and delivery
Planning CT was acquired as 3D or 4D-CT with retrospective
amplitude-based image sorting. If necessary, an additional 3D-CT
was performed in free breathing to allow for contrast i.v. injection.
Gross tumor volume (GTV) was contoured as the visible tumor in
the planning CT supplemented by information from i.v. contrast
3D-CT or further imaging including FDG-PET or magnetic reso-
nance imaging (MRI) if available. For non-SBRT treatments, an
additional clinical target volume (CTV) was generated with a
5 mm margin around the GTV. An additional margin was added
to create the planning target volume (PTV). For SBRT, the internal
target volume (ITV) was generated as a composite GTV from the
different amplitude-based reconstructed CT scans complemented
by a margin of 5 mm to derive the planning target volume (PTV);
no separate CTV was generated for SBRT.
All plans were calculated by a radiation therapy technologist
using institutional constraints for the organs at risk and target pre-
scription standards. For the first radiation treatment, institutional
constraints for thoracic irradiation were based on published rec-
ommendations (QUANTEC) [19–21]. For re-irradiation, there was
a case-by-case decision on cumulative allowance (Spinal cord:
according to Nieder et al. [22]; esophagus and bronchial tree
according to published reports on NSCLC dose escalation or SBRT
protocols; cum. EQD2Gy D0.1 cc <100 Gy, if no relevant PTV com-
promise necessary). All plans were reviewed and consented by at
least 2 board certified senior radiation oncologists.
For treatment planning, Eclipse softwareTM (Varian medical sys-
tems) was used. If necessary immobilization by individualized vac-
uum cast or abdominal compression was used.
EQD2 sum plans and statistical analysis
EQD2 sum plans were calculated for all courses of thoracic
radiotherapy using the software solutions Eclipse (Version
15.6.04, ARIA  OIS for Radiation Oncology, Varian Medical Sys-
tems) and MIM Vista (Version 6.7.9, MIM Software Inc. VR, Cleve-
land, OH). First the CT Scans, dose distribution and the structure
sets of all relevant courses were exported from ARIA to MIM. After
inserting the number of fractions, the structures were matched
with the different a/b-values. To calculate the EQD2 the following
formula was used:
EQD2 ¼ D dþ a=bð Þf g= 2Gyþ a=bð Þf g
The a/b-values for the target volume were 10, for the myelon 2
and for the body and the other organs at risk 3. Thereafter MIM
converted the physical dose distributions to EQD2 dose distribu-
tions based on the LQ model above. EQD2 dose distributions were
transferred back to Aria where accumulated dose distributions
were calculated. As a first step, image registration was performed
using rigid automatic bone match (translation and rotations). This
was followed by non-rigid image registration. Accumulated dose
distributions were calculated on the latest CT scan and the corre-
sponding EQD2 plans and plan sums were generated. Dose volume
parameters were calculated for all relevant organs at risk and tar-
get volumes.
Endpoints and toxicity definitions
During treatment, all patients were monitored weekly for acute
treatment related toxicity. Follow-up 6 weeks after completion of
RT and every 3–4 months thereafter included physical examination
and CT, PET-CT or MRI scans where appropriate according to the
physicians discretion until tumor progression. Toxicity was scored
according to the National Cancer Institute CTCAE v4.0 criteria. Tox-










esophageal carcinoma 6 14.3
pleural mesothelioma 3 7.1








ECOG at 1st Re-irradiation
0–1 37 88.1
2–3 5 11.9
ECOG at further re-irradiation
0–1 9 21.4
2–3 1 2.4
Systemic theapies before first re-irradiation
None 13 31.0
Chemotherapy 24 57.1
Targeted Therapy 1 2.4
Immunotherapy 1 2.4
combination 2 4.8
Systemic theapies after first re-irradiation
None 20 47.6
Chemotherapy 15 35.7




Age at first re-RT (years)
median 69.5 years
range 35–92 years
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(>12 weeks after RT) toxicity. Local failure of a lesion was defined
as either reappearance after complete remission or re-growth after
initial partial response in the respective follow-up imaging modal-
ity. Overall survival (OS) was calculated from first re-irradiation
until death or last follow-up, local control from first re-
irradiation until last imaging follow-up.
Statistical analysis:
Regarding radiation treatment parameters, descriptive statistics
e.g. median, maximum and minimum values were calculated.
Overall survival time (OS) and local control were calculated
according to the Kaplan-Meier method. For group comparison,
log rank test was used. For statistical analysis, SPSS version 25
was used.
Results
A total of 42 patients were treated with thoracic re-irradiation,
8 (19.2%) of which received a total of three thoracic radiotherapy
courses and 2 patients (4.8%) four course of thoracic radiotherapy.
62.5% were treated with a locally ablative dose in a primary or oli-
gometastatic setting at first re-irradiation, 25% of patients were
treated with palliative intent for symptom relief. 52.4% of first
re-irradiation were performed as SBRT, 23.8% as hypofractionated
radiotherapy (single dose 3 Gy) and the remainder as conven-
tionally fractionated radiotherapy. 69% of patients received con-
current systemic therapy at first re-irradiation. The median time
between the first and second course of radiotherapywas 14months
(range 2–184 months). Between second and third course and third
and fourth the intervals were 13 months (range 4–31
The median PTV prescription dose (EQD2) was 48.8 Gy10 (range
12.5–128.4 Gy10) for all RT courses individually or 54.0 Gy10 (range
22–128.4 Gy10), 49.2 Gy10 (range 12.5–120.8 Gy10) and 39 Gy10
(range 39–39 Gy10) for the individual RT courses respectively.
Overall 28.6% of patients had a PTV overlap of more than 25%,
16.8% an overlap of more than 50%. In 28.6% of patients there
was an overlap of the 50% isodose lines without an actual PTV
overlap. Further dose and dose-volume parameters for the PTV of
the accumulated EQD2 dose distributions in table 2.
Regarding OAR, the majority of patients received cumulative
doses between 70 Gy3 and 100 Gy3 (Table 3). In patients where
cumulative OAR doses exceeded 100 Gy3 the bronchial tree
received a maximum D0.1 cc of 187.3 Gy3 (n = 7, median
130.6 Gy3), the esophagus a D0.1 cc of 103.8 Gy3 (n = 1), the aorta
a D0.1 cc of 216.1 Gy3 (n = 5; median 110.2 Gy3), the Aae. pul-
monalis a D0.1 cc of of 187.8 Gy (n = 7, median 121.7 Gy3). In 19
patients, the cumulative D1cc for the lungs exceed 100 Gy and
maxima ranged from 157.9 to 253.9 Gy3). EQD2 dose statistics
for the organs at risk are shown in Table 3.
Regarding clinical outcome the median follow-up from first re-
RT was 13 months (range 1–45 months). Median OS of all patients
after first re-irradiation was 19 months (range 1–45 months). At
the time of analysis 18 patients were still alive. The 12-month local
control after a course of re-irradiation was 52.6%. Figs. 1 and 2
show the Kaplan-Meier curves for overall survival and local control
measured after the first course of re-irradiation.
In total 80% of patients suffered from a mild G1–G2 toxicity,
mostly cough (15%) and dysphagia due to esophagitis (15%). Only
one patient suffered from a high grade complication (G5). This
patient developed a fatal esophageal rupture 16 months after re-
re-irradiation of an NSCLC (esophagus accumulated
D1cc = 48.4 Gy3). Five years prior to reirradiation, this patient
was treated with an initial course of radiotherapy with
20  2 Gy to the centrally located tumor and then a second course
of SBRT for a lung metastases (dose overlap 8 Gy). Clinically, the
patient suffered from a viral esophagitis (Herpes Simplex Virus,
HSV) at the time of the rupture. Table 4 shows the acute
(<12 weeks) and late (>12 weeks) toxicities after radiotherapy.
When analyzing the outcome of patients with an interval
between the courses of radiation treatment of 6 months and
>6 months separately, the median survival of patients with an
interval of 6 months was 14 months (range 1–24 months) and
for patients with an interval >6 months 22 months (range 1–
45 months). The difference in survival was statistically significant
(p = 0.034). Fig. 3 shows the survival in the 2 subgroups.
Discussion
There is no generally accepted recommendation regarding dose,
fractionation and volume in case of thoracic re-irradiation,
although it is quite commonly performed in recent years with
acceptable toxicities and a benefit regarding local or symptom con-
trol [4,8,11–15,17,23–31]. Dose schemes depend on a number of
factors: total dose in the first RT series, indication of the re-
irradiation (symptom control vs. locally ablative treatment), loca-
tion and distance to organs at risk as well as technical approaches
of the treating institution.
The goal of this analysis was to further elaborate on the safety
and efficacy of thoracic reirradiation by overlaying all treatment
plans with non-rigid image registration after EQD2Gy recalcula-
tion, recording cumulative doses to OARs and possibly correlating
these with the observed  G3 toxicity. There are only few pub-
lished data based on EQD2 sum plans in patients receiving re-
irradiation [9,32].
When looking at the applied EQD2 doses in the sum plans in our
analysis, the majority of OAR received cumulative EQD2Gy doses
between 70 and 100 Gy3. Still, for up to 16% of the patients maxi-
mum doses (D0.1 cc) to individual organs at risk exceeded doses
well above 100 Gy3, e.g. Aorta (D0.1 cc = 216.11 Gy3). Yet we report
only one high-grade toxicity, which was probably the result of a
clinical apparent HSV-esophagitis, although an association with
the radiation treatment can‘t be excluded.
As for the lung as a major organ at risk the median EQD2 Dmean
(10.1 Gy; range: 1.9–17.9 Gy3) and V20Gy3 (13.6%, range: 3.4–
36.7%) in the sum plans were well within dose constraints
accepted in the primary treatment setting [20,33–35]. No
increased risk for pneumonitis was observed in our cohort. In case
of re-irradiation a similar V20 Gy with 15% and 17% was published
by Meijneke et al. and Sumita et al. [9,26]. This probably reflects
a strict adherence to common dose constraints for the lung tissue.
Sill, high cumulative have also been observed in small volumes in
our series without increasing the risk for toxicity (range D1cc up to
253.9 Gy3). Generally acceptable >G3 lung tissue toxicity has been
reported in the literature, emphasizing the feasibility of re-
irradiation, especially in smaller volumes [6,8,26,28,32].
A considerable number of patients received a D0.1 cc >70 Gy3
(n = 24) and >100 Gy3 (n = 7 to the bronchial tree. There were no
incidences of bronchial necrosis, obstruction or bleeding observed.
Table 2
Accumulated EQD2 dose characteristics for the planning target volume (PTV).
Median Range
Volume in cc 276 40–1115
V60 Gy10 in % 64.10 0–100
V80 Gy10 in % 11.00 0–98.5
V100 Gy10 in % 4.12 0–88
D1cc in Gy10 108.40 60.7–324.9
Dmax in Gy10 114.10 62.7–363.6
Dmean in Gy10 65.60 35.3–179.6
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This is consistent with data published by Brinkley et al. and Ogawa
et al. [6,31]. They both reported EQD2 sum doses of >200 Gy3 to the
bronchial tree without G3 toxicity, noticeably with only few
patients receiving >100 Gy3. However, as Peulen et al. pointed
out a certain caution should be applied in centrally located tumors
with larger target volumes, as they experienced 3 patients with G5
bleeding complications after re-irradiation for centrally located
tumors [24]. Total cumulative doses of up to 100 Gy3 to the bron-
chial system appear to be safely applicable in the re-treatment set-
ting. Above 100 Gy3 the data is limited, and toxicities have been
observed, although no conclusion can be drawn with regards to
safe EQD2Gy doses. Caution should be applied in large, centrally
located tumors where retreatment volumes significantly overlap
the bronchial tree.
Generally high doses are given to the esophagus also in the pri-
mary setting, e.g. for curatively treated lung cancer [21]. Total
doses to the esophagus during re-irradiation are usually not much
higher, with most patients receiving around 70 Gy3, only few more
than 100 Gy3 [6,9,26,32]. In our cohort only one patient had a
Dmax exceeding 100 Gy3. Therefore, no firm conclusion can be
drawn above 100 Gy EQD2Gy.
Regarding the great vessels, a number of patients received a
D0.1 cc of >70 Gy3 (aorta: n = 19; Aa. pulm.: n = 23), but only
few patients (aorta: n = 5; Aa. pulm.: n = 7) D0.1 cc >100 Gy3. No
Table 3
Accumulated EQD2 dose statistics for the organs at risk.
Median Maximum Minimum
Aorta 0.1 cc >70 Gy (n = 19) D(0,1 cc) in Gy3 79.10 216.11 70.87
D(mean) in Gy3 27.69 44.20 11.01
0.1 cc >100 Gy (n = 5) D(0,1 cc) in Gy3 110.19 216.11 104.43
D(mean) in Gy3 35.69 41.41 11.01
Aae. pulmonalis 0.1 cc >70 Gy (n = 23) D(0,1 cc) in Gy3 87.24 187.80 70.73
D(mean) in Gy3 30.10 64.95 10.83
0.1 cc >100 Gy (n = 7) D(0,1 cc) in Gy3 121.68 187.80 100.39
D(mean) in Gy3 23.53 64.95 12.76
Bronchial tree 0.1 cc >70 Gy (n = 24) D(0,1 cc) in Gy3 81.99 187.33 70.49
D(mean) in Gy3 46.31 63.97 23.19
0.1 cc >100 Gy (n = 7) D(0,1 cc) in Gy3 130.58 187.33 112.32
D(mean) in Gy3 31.96 59.06 23.19
Esophagus 0.1 cc >70 Gy (n = 17) D(0,1 cc) in Gy3 81.04 103.78 70.15
D(mean) in Gy3 32.78 60.57 12.64
0.1 cc >100 Gy (n = 1) D(0,1 cc) in Gy3 103.78 103.78 103.78
D(mean) in Gy3 46.08 46.08 46.08
Heart 0.1 cc >70 Gy (n = 4) D(0,1 cc) in Gy3 74.61 81.08 70.50
D(mean) in Gy3 12.68 18.78 5.61
Lung 1 cc >70 Gy (n = 30) D(1 cc) in Gy3 123.88 253.86 72.14
D(mean) in Gy3 11.05 17.85 3.25
V(20 Gy3) in % 14.86 36.73 2.71
1 cc >70 Gy (n = 19) D(1 cc) in Gy3 157.86 253.86 100.46
D(mean) in Gy3 11.02 17.85 3.44
V(20 Gy3) in % 14.83 36.73 3.79
Spinal cord 0.1 cc >50 Gy (n = 6) D(0,1 cc) in Gy3 57.75 68.30 53.58
D(mean) in Gy3 21.38 24.64 18.64
Fig. 1. Survival of patients after first re-irradiation (n = 42).
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Table 4
Acute toxicity (<12 weeks) and late toxicity (>12 weeks) after radiotherapy.
Acute toxicity (<12 weeks) Late toxicity (>12 weeks)
G1–G2 G3–G4 G5 G1–G2 G3–G4 G5
Cough 8 0 0 3 0 0
Dyspnoea 4 0 0 2 0 0
Pneumonitis 1 0 0 1 0 0
Bleeding 0 0 0 0 0 0
Esophagitis 2 0 0 – – –
Dysphagia 5 0 0 0 0 0
Pain (Thorax) 1 0 0 0 0 0
Fibrosis – – – 1 0 0
Other 4 0 0 0 0 1*
Sum 30 0 0 8 0 1
* Esophageal rupture.
Fig. 3. Survival of patients after first re-irradiation for patients with an interval between RT courses 6 months and >6 months (n = 42).
Fig. 2. Local control of lesions after re-irradiation (n = 48).
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vascular complications were observed. Generally, this is congruent
with published data. Binkley et al. published a dose to the aorta of
up to 200 Gy3 without toxicity [32]. Evans et al. however experi-
enced 2 G5 toxicities to the Aorta in 35 patients receiving re-
irradiation with a physical dose sum of >120 Gy [36]. Kilburn
et al. reported one Grade 5 aorta-esophageal fistula with an esti-
mated EQD2 to the Aorta of 200 Gy [8]. As a conclusion, a total dose
of 100 Gy3 seems safe in the setting of re-irradiation. Above this,
due to the limited number of patients treated there is some uncer-
tainty and severe toxicity has been reported in a small number of
patients receiving EQD2Gy doses greater than 120 Gy3.
The efficacy of the re-irradiation in our cohort was judged by
analyzing overall survival (OS) and local control (LC) within the
irradiated area. With a median OS of 19 months from the time of
first re-irradiation, OS in our cohort was favorable and exceeded
most published data for patients with primary lung cancer or lung
lesions of different primary entity treated with conventional re-RT
with a range of 3–7 months [11–15,25,37,38]. Considerably longer
median OSwas published byWu et al. (median survival 14months)
and Griffioen et al. (median survival 13.5 Gy), both including
patients with NSCLC and SCLC. They used high dose re-
irradiation with a median total dose of 51 Gy (Wu et al.) and
60 Gy (Griffioen et al). Data regarding survival after SBRT, also
including patients with primary or secondary lung lesions showed
even a better median survival of 20–30 months [6,8,10,17,18,39],
with our median OS of 19 months being at the lower published
range. In this context we observed that patients with an interval
of >6 months between radiation courses had a significantly longer
overall survival. Although a selection bias can’t be excluded due to
the retrospective nature of this data, it also reflects on the dynamic
of a disease. For fast progressing disease, the benefit for re-
irradiation regarding OS might be limited. This should be taken
into consideration for overall treatment decision making.
Regarding local control the 1-year local control of 52.6% in our
cohort is within the published range of 52–95%, though at the lower
range [9,10,18,24,26,28,40–42]. Given that published data on the
higher range of local al control refer to stereotactic re-irradiation,
52.6% is a reasonable local control given that our cohort included
both patients re-irradiated in local curative intent with SBRT and
a palliative approach. Still, this also reflects the necessity for future
research to better define patient cohorts which may benefit most
from a re-irradiation approach and then select the appropriate
and maximally safe/selective radiation dose according to the treat
intent.
Although we observed a wide range of applied doses in our
patient cohort, dose–response modelling was not possible due to
the low observed rate of late toxicities. Within our reported EQD2
dose ranges re-irradiation, even multiple times appeared to be safe
and effective. The strength of our analysis in contrast to previous
analysis is that we not only calculated cumulative EQD2 sum plan
to investigate maximally applied doses, but also report on dose-
volume parameters like D0.1 cc, D1cc, V70–100 Gy to give some
guidance of how to interpret and possibly apply our results in daily
routine to assure safe re-irradiation.Nevertheless,we are aware that
our data suffers the same limitations of virtually all re-irradiation
reports due to its retrospective nature and highly selected patient
cohorts. There is a need for collection and evaluation of re-
irradiation in a prospective manner to get higher quality data with
regards to safety, toxicity and quality of life to derive better recom-
mendation for patient selection and safe re-irradiation doses.
Additionally, future research on re-irradiation should explore
strategies to improve the therapeutic ratio. Protons for example
might offer dosimetrical and biological advantages due to their
unique physical properties. Also, new technologies improving on
the image guidance and facilitating daily adaptive treatment like
the current MR linac implementations might help to reduce the
margins necessary to achieve reasonable local control and to
reduce OAR exposure to radiation. Systemic treatment option like
targeted therapies as well as immunotherapy approaches need to
be taken into account as well, either as alternatives to re-
irradiation or as companion treatment to allow lower and thus
safer radiation dose for an equivalent local effect.
As a conclusion it can be stated that even though several organs
at risk received a maximum D1cc of >100 Gy, thoracic irradiation
proved to be safe with acceptable toxicities and effective with a
good overall survival and local control given the inhomogeneous,
‘‘every day” patient population. Nevertheless, prospective data col-
lection with proper analysis of cumulative plan sum are needed to
derive robust recommendation for re-irradiation in the thorax.
Declaration of Competing Interest
The authors declare that they have no known competing finan-
cial interests or personal relationships that could have appeared
to influence the work reported in this paper.
References
[1] Johnson BE. Second lung cancers in patients after treatment for an initial lung
cancer. J Natl Cancer Inst 1998;90:1335–45.
[2] Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and
second primary lung cancer in early-stage lung cancer survivors followed with
routine computed tomography surveillance. J Thorac Cardiovasc Surg
2013;145:75–81.
[3] Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-
analysis of concomitant versus sequential radiochemotherapy in locally
advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181–90.
[4] Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, et al.
Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a
single institutional study. J Radiat Res 2016;57:55–61.
[5] Loi M, Duijm M, Baker S, Rossi L, Grunhagen D, Verhoef C, et al. Stereotactic
body radiotherapy for oligometastatic soft tissue sarcoma. Radiol Med 2018.
[6] Ogawa Y, Shibamoto Y, Hashizume C, Kondo T, Iwata H, Tomita N, et al. Repeat
stereotactic body radiotherapy (SBRT) for local recurrence of non-small cell
lung cancer and lung metastasis after first SBRT. Radiat Oncol 2018;13:136.
[7] Valakh V, Miyamoto C, Micaily B, Chan P, Neicu T, Li S. Repeat stereotactic body
radiation therapy for patients with pulmonary malignancies who had
previously received SBRT to the same or an adjacent tumor site. J Cancer Res
Ther 2013;9:680–5.
[8] Meijneke TR, Petit SF, Wentzler D, Hoogeman M, Nuyttens JJ. Reirradiation and
stereotactic radiotherapy for tumors in the lung: dose summation and toxicity.
Radiother Oncol 2013;107:423–7.
[9] Reyngold M, Wu AJ, McLane A, Zhang Z, Hsu M, Stein NF, et al. Toxicity and
outcomes of thoracic re-irradiation using stereotactic body radiation therapy
(SBRT). Radiat Oncol 2013;8:99.
[10] Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH,
et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT)
techniques as first or second course of treatment. Radiother Oncol
2014;110:505–10.
[11] Ebara T, Tanio N, Etoh T, Shichi I, Honda A, Nakajima N. Palliative re-irradiation
for in-field recurrence after definitive radiotherapy in patients with primary
lung cancer. Anticancer Res 2007;27:531–4.
[12] Kramer GW, Gans S, Ullmann E, van Meerbeeck JP, Legrand CC, Leer JW.
Hypofractionated external beam radiotherapy as retreatment for symptomatic
non-small-cell lung carcinoma: an effective treatment?. Int J Radiat Oncol Biol
Phys 2004;58:1388–93.
[13] Gressen EL, Werner-Wasik M, Cohn J, Topham A, Curran Jr WJ. Thoracic
reirradiation for symptomatic relief after prior radiotherapeutic management
for lung cancer. Am J Clin Oncol 2000;23:160–3.
[14] Montebello JF, Aron BS, Manatunga AK, Horvath JL, Peyton FW. The
reirradiation of recurrent bronchogenic carcinoma with external beam
irradiation. Am J Clin Oncol 1993;16:482–8.
[15] Jackson MA, Ball DL. Palliative retreatment of locally-recurrent lung cancer
after radical radiotherapy. Med J Aust 1987;147:391–4.
[16] Rodrigues G, Videtic GM, Sur R, Bezjak A, Bradley J, Hahn CA, et al. Palliative
thoracic radiotherapy in lung cancer: an American Society for Radiation
Oncology evidence-based clinical practice guideline. Pract Radiat Oncol
2011;1:60–71.
[17] Horne ZD, Dohopolski MJ, Clump DA, Burton SA, Heron DE. Thoracic
reirradiation with SBRT for residual/recurrent and new primary NSCLC
within or immediately adjacent to a prior high-dose radiation field. Pract
Radiat Oncol 2018;8:e117–23.
[18] Patel NR, Lanciano R, Sura K, Yang J, Lamond J, Feng J, et al. Stereotactic body
radiotherapy for re-irradiation of lung cancer recurrence with lower biological
effective doses. J Radiat Oncol 2015;4:65–70.
C. Schröder et al. / Radiotherapy and Oncology 152 (2020) 56–62 61
[19] Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, et al.
Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys
2010;76:S77–85.
[20] Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, et al.
Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys
2010;76:S70–6.
[21] Werner-Wasik M, Yorke E, Deasy J, Nam J, Marks LB. Radiation dose-volume
effects in the esophagus. Int J Radiat Oncol Biol Phys 2010;76:S86–93.
[22] Nieder C, Grosu AL, Andratschke NH, Molls M. Update of human spinal cord
reirradiation tolerance based on additional data from 38 patients. Int J Radiat
Oncol Biol Phys 2006;66:1446–9.
[23] Sumita K, Harada H, Asakura H, Ogawa H, Onoe T, Murayama S, et al. Re-
irradiation for locoregionally recurrent tumors of the thorax: a single-
institution, retrospective study. Radiat Oncol 2016;11:104.
[24] Binkley MS, Hiniker SM, Chaudhuri A, Maxim PG, Diehn M, Loo Jr BW, et al.
Dosimetric factors and toxicity in highly conformal thoracic reirradiation. Int J
Radiat Oncol Biol Phys 2016;94:808–15.
[25] Tada T, Fukuda H, Matsui K, Hirashima T, Hosono M, Takada Y, et al. Non-
small-cell lung cancer: reirradiation for loco-regional relapse previously
treated with radiation therapy. Int J Clin Oncol 2005;10:247–50.
[26] Wu KL, Jiang GL, Qian H, Wang LJ, Yang HJ, Fu XL, et al. Three-dimensional
conformal radiotherapy for locoregionally recurrent lung carcinoma after
external beam irradiation: a prospective phase I-II clinical trial. Int J Radiat
Oncol Biol Phys 2003;57:1345–50.
[27] Okamoto Y, Murakami M, Yoden E, Sasaki R, Okuno Y, Nakajima T, et al.
Reirradiation for locally recurrent lung cancer previously treated with
radiation therapy. Int J Radiat Oncol Biol Phys 2002;52:390–6.
[28] Griffioen GH, Dahele M, de Haan PF, van de Ven PM, Slotman BJ, Senan S. High-
dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung
Cancer 2014;83:356–62.
[29] Drodge CS, Ghosh S, Fairchild A. Thoracic reirradiation for lung cancer: a
literature review and practical guide. Ann Palliat Med 2014;3:75–91.
[30] Poltinnikov IM, Fallon K, Xiao Y, Reiff JE, Curran Jr WJ, Werner-Wasik M.
Combination of longitudinal and circumferential three-dimensional
esophageal dose distribution predicts acute esophagitis in hypofractionated
reirradiation of patients with non-small-cell lung cancer treated in stereotactic
body frame. Int J Radiat Oncol Biol Phys 2005;62:652–8.
[31] De Ruysscher D, Faivre-Finn C, Le Pechoux C, et al. High-dose re-irradiation
following radical radiotherapy for non-small-cell lung cancer. Lancet Oncol
2014;15:e620–4.
[32] Hearn JW, Videtic GM, Djemil T, Stephans KL. Salvage stereotactic body
radiation therapy (SBRT) for local failure after primary lung SBRT. Int J Radiat
Oncol Biol Phys 2014;90:402–6.
[33] Peulen H, Karlsson K, Lindberg K, Tullgren O, Baumann P, Lax I, et al. Toxicity
after reirradiation of pulmonary tumours with stereotactic body radiotherapy.
Radiother Oncol 2011;101:260–6.
[34] Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo Jr BW, et al. Stereotactic
ablative radiotherapy for reirradiation of locally recurrent lung tumors. J
Thorac Oncol 2012;7:1462–5.
[35] Trovo M, Minatel E, Durofil E, Polesel J, Avanzo M, Baresic T, et al. Stereotactic
body radiation therapy for re-irradiation of persistent or recurrent non-small
cell lung cancer. Int J Radiat Oncol Biol Phys 2014;88:1114–9.
[36] Bradley JD, Bae K, Graham MV, Byhardt R, Govindan R, Fowler J, et al. Primary
analysis of the phase II component of a phase I/II dose intensification study
using three-dimensional conformal radiation therapy and concurrent
chemotherapy for patients with inoperable non-small-cell lung cancer:
RTOG 0117. J Clin Oncol 2010;28:2475–80.
[37] Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al.
Standard-dose versus high-dose conformal radiotherapy with concurrent and
consolidation carboplatin plus paclitaxel with or without cetuximab for
patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a
randomised, two-by-two factorial phase 3 study. Lancet Oncol
2015;16:187–99.
[38] Schild SE, McGinnis WL, Graham D, Hillman S, Fitch TR, Northfelt D, et al.
Results of a Phase I trial of concurrent chemotherapy and escalating doses of
radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol
Phys 2006;65:1106–11.
[39] Evans JD, Gomez DR, Amini A, Rebueno N, Allen PK, Martel MK, et al. Aortic
dose constraints when reirradiating thoracic tumors. Radiother Oncol
2013;106:327–32.
[40] Cetingoz R, Arican-Alicikus Z, Nur-Demiral A, Durmak-Isman B, Bakis-Altas B,
Kinay M. Is re-irradiation effective in symptomatic local recurrence of non
small cell lung cancer patients? A single institution experience and review of
the literature. J BUON 2009;14:33–40.
[41] Green N, Melbye RW. Lung cancer: retreatment of local recurrence after
definitive irradiation. Cancer 1982;49:865–8.
[42] Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, et al. Stereotactic
body radiation therapy for patients with lung cancer previously treated with
thoracic radiation. Int J Radiat Oncol Biol Phys 2010;78:1387–93.
62 Re-irradiation in the thorax – An analysis of efficacy and safety based on accumulated EQD2 doses
